OBJECTIVE: To determine the presence of raised titres of anti-serum amyloid P component (SAP) antibodies in patients with systemic lupus erythematosus (SLE) and to evaluate their correlation with clinical disease by the SLEDAI and clinical manifestations. METHODS: 452 samples were screened for raised anti-SAP antibody titres by an ELISA. Clinical measures and SLEDAI scores were independently reviewed from medical records. 21 serial samples from 7 patients with SLE were assessed for a change in anti-SAP antibody titres after treatment. RESULTS: Raised anti-SAP antibody titres were detected in 145/328 (44%) SLE samples. In 112 randomly selected samples, 69/112 (62%) patients had raised anti-SAP antibodies and anti-dsDNA antibody titres, whereas only 32/112 (28%) had raised anti-dsDNA antibody titres without raised anti-SAP antibody titres. The mean titre of anti-SAP antibodies in patients with active disease was higher than in patients with inactive disease and controls. SLEDAI scores, assessed in 54 patients, were raised in 26/31 (84%) patients with raised anti-SAP antibody titres. A SLEDAI score >or=8 was found in 16/31 (52%) patients with raised anti-SAP antibody titres but in only 5/23 (22%) patients without raised titres. No specific pattern of disease was detected in patients with or without raised titres of anti-SAP antibodies. Serial sampling from patients with active SLE and raised anti-SAP antibody titres showed that anti-SAP antibody titres decreased after treatment and correlated with clinical improvement. CONCLUSION: Raised anti-SAP antibody titres detected in patients with SLE correlate with disease activity and decrease with improvement of clinical disease, and thus may serve as an additional prognostic marker.
OBJECTIVE: To determine the presence of raised titres of anti-serum amyloid P component (SAP) antibodies in patients with systemic lupus erythematosus (SLE) and to evaluate their correlation with clinical disease by the SLEDAI and clinical manifestations. METHODS: 452 samples were screened for raised anti-SAP antibody titres by an ELISA. Clinical measures and SLEDAI scores were independently reviewed from medical records. 21 serial samples from 7 patients with SLE were assessed for a change in anti-SAP antibody titres after treatment. RESULTS: Raised anti-SAP antibody titres were detected in 145/328 (44%) SLE samples. In 112 randomly selected samples, 69/112 (62%) patients had raised anti-SAP antibodies and anti-dsDNA antibody titres, whereas only 32/112 (28%) had raised anti-dsDNA antibody titres without raised anti-SAP antibody titres. The mean titre of anti-SAP antibodies in patients with active disease was higher than in patients with inactive disease and controls. SLEDAI scores, assessed in 54 patients, were raised in 26/31 (84%) patients with raised anti-SAP antibody titres. A SLEDAI score >or=8 was found in 16/31 (52%) patients with raised anti-SAP antibody titres but in only 5/23 (22%) patients without raised titres. No specific pattern of disease was detected in patients with or without raised titres of anti-SAP antibodies. Serial sampling from patients with active SLE and raised anti-SAP antibody titres showed that anti-SAP antibody titres decreased after treatment and correlated with clinical improvement. CONCLUSION: Raised anti-SAP antibody titres detected in patients with SLE correlate with disease activity and decrease with improvement of clinical disease, and thus may serve as an additional prognostic marker.
Authors: A Familian; B Zwart; H G Huisman; I Rensink; D Roem; P L Hordijk; L A Aarden; C E Hack Journal: J Immunol Date: 2001-07-15 Impact factor: 5.422
Authors: Irith Baumann; Wasilis Kolowos; Reinhard E Voll; Bernhard Manger; Udo Gaipl; Winfried L Neuhuber; Thomas Kirchner; Joachim R Kalden; Martin Herrmann Journal: Arthritis Rheum Date: 2002-01
Authors: M Soma; T Tamaoki; H Kawano; S Ito; M Sakamoto; Y Okada; Y Ozaki; S Kanba; Y Hamada; T Ishihara; S Maeda Journal: Biochem Biophys Res Commun Date: 2001-08-10 Impact factor: 3.575
Authors: M B Pepys; J Herbert; W L Hutchinson; G A Tennent; H J Lachmann; J R Gallimore; L B Lovat; T Bartfai; A Alanine; C Hertel; T Hoffmann; R Jakob-Roetne; R D Norcross; J A Kemp; K Yamamura; M Suzuki; G W Taylor; S Murray; D Thompson; A Purvis; S Kolstoe; S P Wood; P N Hawkins Journal: Nature Date: 2002-05-16 Impact factor: 49.962
Authors: Y Levy; Y Sherer; A Ahmed; P Langevitz; J George; F Fabbrizzi; J Terryberry; M Meissner; M Lorber; J B Peter; Y Shoenfeld Journal: Lupus Date: 1999 Impact factor: 2.911
Authors: Margherita Zen; Nicola Bassi; Carla Campana; Silvano Bettio; Elena Tarricone; Linda Nalotto; Anna Ghirardello; Andrea Doria Journal: Auto Immun Highlights Date: 2010-11-04
Authors: Christina Janko; Sandra Franz; Luis E Munoz; Stefan Siebig; Silke Winkler; Georg Schett; Kirsten Lauber; Ahmed Sheriff; Johan van der Vlag; Martin Herrmann Journal: Front Immunol Date: 2011-12-02 Impact factor: 7.561